trial

Ginkgo Biloba Extract for Schizophrenia

NCTId NCT01524380
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 124 (actual)
Sponsored by Beijing HuiLongGuan Hospital
Primary completion 2013-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
124 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-09
Primary completion
2013-06
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Ginkgo Biloba Extract

Sponsors

Beijing HuiLongGuan HospitalLead Sponsor

Investigators

1
Xiang Y Zhang, MD/PhDPrincipal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
124
Phase
NA
Primary Completion Date
2013-06
Status
COMPLETED
relationships
The graph out of here
drug
Ginkgo Biloba Extract
drug
lead_sponsor
Beijing HuiLongGuan Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Xiang Y Zhang, MD/PhD
person